Juanjuan Zhou , Jinbo Zhan , Hongjiao Zhang , Liping Liu , Yan He , Yi Le , Weiqi Liu , Ling Zhou , Xiaojun Xiang
{"title":"PCDHB家族在胃癌中的综合评价:预后意义、免疫浸润及PCDHB5致癌作用的实验验证","authors":"Juanjuan Zhou , Jinbo Zhan , Hongjiao Zhang , Liping Liu , Yan He , Yi Le , Weiqi Liu , Ling Zhou , Xiaojun Xiang","doi":"10.1016/j.intimp.2025.115318","DOIUrl":null,"url":null,"abstract":"<div><div>The protocadherin B family genes (PCDHBs) play a significant role in tumor progression, yet their specific functions in gastric cancer remain insufficiently understood. This study aims to investigate the expression patterns of PCDHBs in gastric cancer, explore their influence on immune infiltration and patient prognosis, and preliminarily validate the functional role and underlying mechanisms of PCDHB5 through in vitro experiments. Using multi-omics data from the TCGA database, we found that most PCDHBs are significantly upregulated in gastric cancer, with missense mutations being the most common mutation type. Furthermore, we found the positive correlation between PCDHBs and the ESTIMATE score, as well as the TIDE score, and the negative correlation with microsatellite instability and tumor mutational burden, suggesting their involvement in shaping an immunosuppressive tumor microenvironment and poor response to immunotherapy. Notably, through LASSO regression and multivariate analysis, PCDHB5 was identified as a key gene correlated with overall survival (OS) and progression-free survival (PFS) in gastric cancer. Based on these findings, we constructed a nomogram incorporating PCDHB5 expression to predict the prognosis of gastric cancer patients. Functional assays and molecular biology techniques confirmed that PCDHB5 is highly expressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion, potentially through the regulation of the Wnt/β-catenin signaling pathway. In conclusion, this study provides a comprehensive analysis of PCDHBs in gastric cancer, revealing their roles in tumor immunity and prognosis, and highlights the functional role of PCDHB5 in gastric cancer progression and its potential as a therapeutic target.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"163 ","pages":"Article 115318"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive evaluation of the PCDHB family in gastric cancer: Prognostic significance, immune infiltration, and experimental validation of PCDHB5's oncogenic role\",\"authors\":\"Juanjuan Zhou , Jinbo Zhan , Hongjiao Zhang , Liping Liu , Yan He , Yi Le , Weiqi Liu , Ling Zhou , Xiaojun Xiang\",\"doi\":\"10.1016/j.intimp.2025.115318\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The protocadherin B family genes (PCDHBs) play a significant role in tumor progression, yet their specific functions in gastric cancer remain insufficiently understood. This study aims to investigate the expression patterns of PCDHBs in gastric cancer, explore their influence on immune infiltration and patient prognosis, and preliminarily validate the functional role and underlying mechanisms of PCDHB5 through in vitro experiments. Using multi-omics data from the TCGA database, we found that most PCDHBs are significantly upregulated in gastric cancer, with missense mutations being the most common mutation type. Furthermore, we found the positive correlation between PCDHBs and the ESTIMATE score, as well as the TIDE score, and the negative correlation with microsatellite instability and tumor mutational burden, suggesting their involvement in shaping an immunosuppressive tumor microenvironment and poor response to immunotherapy. Notably, through LASSO regression and multivariate analysis, PCDHB5 was identified as a key gene correlated with overall survival (OS) and progression-free survival (PFS) in gastric cancer. Based on these findings, we constructed a nomogram incorporating PCDHB5 expression to predict the prognosis of gastric cancer patients. Functional assays and molecular biology techniques confirmed that PCDHB5 is highly expressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion, potentially through the regulation of the Wnt/β-catenin signaling pathway. In conclusion, this study provides a comprehensive analysis of PCDHBs in gastric cancer, revealing their roles in tumor immunity and prognosis, and highlights the functional role of PCDHB5 in gastric cancer progression and its potential as a therapeutic target.</div></div>\",\"PeriodicalId\":13859,\"journal\":{\"name\":\"International immunopharmacology\",\"volume\":\"163 \",\"pages\":\"Article 115318\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International immunopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567576925013098\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925013098","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Comprehensive evaluation of the PCDHB family in gastric cancer: Prognostic significance, immune infiltration, and experimental validation of PCDHB5's oncogenic role
The protocadherin B family genes (PCDHBs) play a significant role in tumor progression, yet their specific functions in gastric cancer remain insufficiently understood. This study aims to investigate the expression patterns of PCDHBs in gastric cancer, explore their influence on immune infiltration and patient prognosis, and preliminarily validate the functional role and underlying mechanisms of PCDHB5 through in vitro experiments. Using multi-omics data from the TCGA database, we found that most PCDHBs are significantly upregulated in gastric cancer, with missense mutations being the most common mutation type. Furthermore, we found the positive correlation between PCDHBs and the ESTIMATE score, as well as the TIDE score, and the negative correlation with microsatellite instability and tumor mutational burden, suggesting their involvement in shaping an immunosuppressive tumor microenvironment and poor response to immunotherapy. Notably, through LASSO regression and multivariate analysis, PCDHB5 was identified as a key gene correlated with overall survival (OS) and progression-free survival (PFS) in gastric cancer. Based on these findings, we constructed a nomogram incorporating PCDHB5 expression to predict the prognosis of gastric cancer patients. Functional assays and molecular biology techniques confirmed that PCDHB5 is highly expressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion, potentially through the regulation of the Wnt/β-catenin signaling pathway. In conclusion, this study provides a comprehensive analysis of PCDHBs in gastric cancer, revealing their roles in tumor immunity and prognosis, and highlights the functional role of PCDHB5 in gastric cancer progression and its potential as a therapeutic target.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.